- Company
- Alvogen is targeting patents for Roche's Avastin
- by Kim, Jin-Gu Aug 13, 2021 05:58am
- Alvogen Korea has started patenting Roche's blockbuster anti-cancer drug Avastin (Bevacizumab). Two types of Avastin biosimilar are already licensed in Korea. According to the pharmaceutical industry on the 12th, Alvogen Korea recently filed an invalid trial on Roche's two patents of Avastin. Roche is registering a total of four patent
- Company
- SGLT-2 inhibitor Forxiga lands in Korea with CKD indication
- by Eo, Yun-Ho Aug 12, 2021 06:05am
- An SLGT-2 inhibitor is soon expected to be available for use in chronic kidney disease (CKD) patients in Korea. According to industry sources, the indication of AstraZeneca’s diabetes treatment ‘Forxiga(dapagliflozin)’ will be expanded to ‘the treatment of chronic kidney disease in patients at risk of progression with and without type
- Company
- Eybelis can be prescribed at general hospitals
- by Eo, Yun-Ho Aug 11, 2021 05:58am
- The new glaucoma treatment ‘Eybelis’ that has been released can now be prescribed at general hospitals in Korea. According to industry sources, Santen Pharmaceutical Korea’s selective EP2 receptor Eybelis Ophthalmic Solution (Omidenepag Isopropyl) has recently passed the review of drug committees (DC) in two of the ‘Big 5’ major hospi
- Company
- Changes after Pfizer and Moderna vaccines' full approval
- by Aug 11, 2021 05:58am
- Expectations are rising that COVID-19 vaccines of multinational pharmaceutical companies such as Pfizer-BioNTech and Moderna will receive full regulatory approval early next month. If the vaccines are formally approved, what changes will we see in the current landscape where people worldwide are already receiving vaccinations under the EUA?
- Company
- Reimbursement for Kymriah will be deliberated by CDRC
- by Eo, Yun-Ho Aug 10, 2021 05:54am
- The discussions on listing the ultra-high-priced, one-shot treatment ‘Kymriah’ for health insurance benefits will begin. According to industry sources, Novartis Korea’s first-in-class CAR-T (chimeric antigen receptor-T) treatment will be put as an agenda for deliberation in September at Health Insurance Review and Assessment Service’s
- Company
- Marken establishs a cGMP cold-chain center in Korea
- by Nho, Byung Chul Aug 10, 2021 05:54am
- A cGMP compliant cold-chain center for the distribution of pharmaceuticals that will soon be complete in Korea is receiving attention. According to industry sources, the global biopharmaceutical·clinical trial logistics company Marken and its parent company UPS have worked together to establish a 1,000-pyeong cold chain storage and distr
- Company
- Antengen Korea's blood cancer treatment Xpovio is approved
- by Eo, Yun-Ho Aug 9, 2021 06:02am
- The Chinese pharmaceutical company Antengene’s blood cancer drug ‘Xpovio’ has entered the domestic market. According to industry sources, Antengene Korea’s first-in-class XPO1 inhibitor Xpovio (Selinexor) was approved by the Ministry of Food and Drug Safety (MFDS) on the 29th of last month. The drug had been previously designated an O
- Company
- Sales of 'Stillen' have declined in two years
- by Chon, Seung-Hyun Aug 8, 2021 06:50pm
- Sales of gastritis treatments containing Artemisia Herb as an active ingredient have decreased. Sales had increased due to reflective profits from withdrawal of Ranitidine, but fell in two years. It is analyzed that Artemisia Herb's sales have decreased as the prescription market has shrunk due to the prolonged COVID-19 outbreak and PPI drugs ha
- Company
- Celltrion's developing next-generation mRNA vaccine platform
- by Lee, Seok-Jun Aug 8, 2021 06:49pm
- Celltrion has started developing next-generation mRNA vaccine platform with TriLink Biotechnology in the U.S. According to the company on the 4th, TriLink is a contract development and manufacturing organization (CDMO) based on the mRNA platform located in San Diego, U.S. It has its own Vactor and Gen3 CleanCap, which are essential for the
- Company
- Pfizer seeks generation change in the ALK market
- by Aug 8, 2021 06:48pm
- Pfizer, which developed the first ALK-targeted treatment, has released a third-generation new product. A new option has emerged in the ALK targeted treatment market, where subsequent drugs were not appropriate. Third-generation drugs are also expected to compete with second-generation products as a primary treatment. Pfizer was approved by
